CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in CNS Pharmaceuticals, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- 0 vs. Q2 2021
- Shares held
- 967.8K
- −379.0K (−28.1%) vs. Q2 2021
- Total value
- $1.44M
- −$1.20M (−45.6%) vs. Q2 2021
- New holders
- 4
- 5 more added
- Sold out
- 4
- 4 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 609,409 | $908.0K | 0.00% | +10,100+1.7% | Added |
| Geode Capital Management, LLC | 107,262 | $159.0K | 0.00% | +7,066+7.1% | Added |
| BlackRock Inc. | 40,718 | $60.0K | 0.00% | −868−2.1% | Reduced |
| Northern Trust Corp | 32,094 | $48.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 29,758 | $44.0K | 0.00% | +29,758 | New |
| Virtu Financial LLC | 22,480 | $33.0K | 0.00% | +1,735+8.4% | Added |
| Citadel Advisors LLC | 21,213 | $32.0K | 0.00% | +21,213 | New |
| Commonwealth Equity Services, LLC | 20,000 | $29.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 17,988 | $27.0K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 16,531 | $24.0K | 0.00% | +16,531 | New |
| Wells Fargo & Company | 13,845 | $20.0K | 0.00% | −50.0% | Reduced |
| Cambridge Investment Research Advisors, Inc. | 11,250 | $17.0K | 0.00% | +1,000+9.8% | Added |
| Alpha Cubed Investments, LLC | 11,000 | $16.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 5,513 | $8.00K | 0.00% | −6,987−55.9% | Reduced |
| Bank of America Corp | 4,886 | $7.00K | 0.00% | +2,886+144.3% | Added |
| Migdal Insurance & Financial Holdings Ltd. | 2,058 | $3.00K | 0.00% | +2,058 | New |
| Capital Analysts, LLC | 1,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Sterling Financial Planning, Inc. | 600 | $1.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 10 | $0 | 0.00% | −4,990−99.8% | Reduced |
| Gradient Investments LLC | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −432,109−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,061−100.0% | Sold out |
| Integrated Advisors Network LLC | 0 | $0 | 0.00% | −10,700−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −4,676−100.0% | Sold out |